The UK’s Medication Crisis: A Growing Threat to Public Health
The United Kingdom is facing a critical challenge in its healthcare system, with access to essential medicines at its most fragile point in recent years. This situation has left patients vulnerable to serious health risks, including strokes, heart attacks, and seizures, due to the inability to obtain necessary medications.
Experts have pointed to global supply chains as a key factor behind this crisis. Complicated funding processes within the UK are exacerbating the issue, leading to life-threatening consequences for patients. The National Health Service (NHS) pays pharmacies a fixed price for each drug it dispenses, but pharmacies must source these drugs at their own cost. When the price of a drug exceeds what the NHS covers, pharmacies face financial losses, making it difficult to maintain adequate stock levels.
This problem has been further compounded by rising medication prices. Over 230 medications are currently on price concession, meaning pharmacies struggle to afford enough stock. As a result, patients are experiencing significant delays and sudden shortages. The conflict in Iran has also contributed to this issue, with disruptions to air freight routes and increased shipping costs driving up the prices of key medicines, particularly those used in cancer treatment.
Pharmacists are deeply concerned that existing shortages of blood pressure, epilepsy, and cancer drugs could worsen due to the ongoing war. In April, the number of drugs on concession reached a record high, with hundreds of pharmacies experiencing price hikes on some of the most commonly prescribed drugs. According to the National Pharmacy Association, some pharmacies have seen prices rise tenfold since February, placing an unsustainable burden on the NHS.
The situation has led to pharmacies operating at a loss, as the NHS reimburses them far less than the actual cost of the drugs. Dr. Leyla Hannbeck, chief executive at the Independent Pharmacies Association, highlights that the list of affected medicines is extensive. “Medicines for thinning the blood, some allergy medications, epilepsy medicines, and cancer drugs are in short supply,” she said. “The list goes on.”
ADHD drugs are also being impacted, causing difficulties for patients who rely on them to maintain their daily routines. Some individuals are suffering from preventable seizures, which can be life-threatening. With hundreds of everyday drugs in short supply, the problem appears to be systemic rather than isolated.
Olivier Picard, chairman of the National Pharmacy Association, explained that the gap between supply and demand has become so wide that pharmacies are sending patients to other locations, often miles away, to obtain their medication. “We are in a position now where we cannot afford to dispense at a loss. The system is simply not working,” he said.
Key Medications in Short Supply
- Allergy medications
- ADHD drugs
- Anti-depressants – including Venlafaxine
- Blood pressure drugs – including ramipril, bisoprolol
- Bipolar medication
- Blood thinners – including apixaban
- Cancer drugs – including Creon and Efudix
- Epilepsy medication
- Eye-drops
- Oxybutynin (for overactive bladder)
Picard emphasized that while there are no immediate shortages directly caused by the conflict in the Middle East, manufacturers warn that supply breakdowns are inevitable. “Even if medicines are available, the conflict is pushing production and transportation costs to such a level that the price the NHS is willing to pay doesn’t cover the cost of manufacturing them,” he said.
Ingredients sourced from the region are also in short supply, affecting the availability of petroleum-based solvents used in many pharmaceutical products. Transportation costs have significantly increased compared to pre-conflict levels.
Other drugs taken by millions of patients are under severe pressure. Apixaban, used to prevent blood clots, and blood pressure drugs like bisoprolol and carvedilol are among those affected. Cancer drugs such as Creon and Efudix are also in short supply, according to Hannbeck. Oxybutynin, used to manage menopause symptoms, is largely out of stock.
Last month, the Department of Health issued a “serious shortage protocol” for ramipril, one of the most widely prescribed blood pressure medications. Patients are now limited to one month’s supply of pills at a time, but many pharmacists are already struggling to meet this requirement.
The UK imports around 75% of its drugs, and even those made in Europe often rely on ingredients shipped from China, India, or the Middle East. Additionally, the government spends less on medicine per patient than many EU countries, making the UK a less attractive buyer.
In response, a spokesperson from the Department of Health stated: “The vast majority of the UK’s licensed medicines are in good supply, and we are working hard to keep it that way. We have established processes to respond to sudden market price increases of medicines. This includes adjusting reimbursement prices based on current market conditions, which helps ensure that pharmacies can continue to obtain medicines for their patients.”
